Kleberg Foundation Archives

A new mechanism for lupus

Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.

Gene network for leukemia factor

Feb. 4, 2021—A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.

WIN for blocking cancer growth

Jan. 21, 2021—William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.

Pancreatic cancer development

Aug. 31, 2017—Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.

HDAC3 role in B-cell development

Aug. 3, 2017—The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.

PET imaging to predict tumor response

Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

New grants bolster Trauma program’s research initiatives

Feb. 9, 2017—Vanderbilt University Medical Center’s Division of Trauma, Emergency General Surgery and Surgical Critical Care was recently awarded two new research grants.

Kleberg Foundation grant bolsters cancer drug discovery efforts

Aug. 3, 2016—The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”